Pasithea Therapeutics

Company snapshot

Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders. We leverage our expertise in the fields of neuroscience, medicinal chemistry, and translational medicine to develop new molecular entities that target the pathophysiology underlying such diseases with the goal of bringin

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Pasithea Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Pasithea Therapeutics.

1. Jun 8, 2026 Clinical update

   A Phase 1 Open-label Study to Assess the Safety for Solid Tumors — Phase 1

2. Jun 5, 2026 Clinical update

   PAS-004 Tablets — Phase 1

3. Jun 5, 2026 Clinical update

   PAS-004 Capsules — Phase 1

View all clinical trial activity →

• What is Pasithea Therapeutics?

  Pasithea Therapeutics is a pharma organization headquartered in Miami Beach, USA. It trades on NYSE under ticker KTTA. Primary therapeutic focus areas include Solid Tumors, RAS Mutation, NF1 Mutation. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent rec

• Is Pasithea Therapeutics publicly traded?

  Yes. Pasithea Therapeutics is listed with ticker KTTA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Pasithea Therapeutics develop or market?

  We link 6 drug profile(s) where Pasithea Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pasithea-therapeutics#company-drugs.

• What are the latest developments for Pasithea Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Pasithea Therapeutics focus on?

  Pasithea Therapeutics focuses on Solid Tumors, RAS Mutation, NF1 Mutation based on our analysis of their pipeline programs and drug development activities.